Track ClearPoint Neuro, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

ClearPoint Neuro, Inc. CLPT Open ClearPoint Neuro, Inc. in new tab

11.64 USD
EPS
-1.00
P/B
18.54
ROE
-149.72
Beta
1.29
Target Price
22.00 USD
ClearPoint Neuro, Inc. logo

ClearPoint Neuro, Inc.

🧾 Earnings Recap – Q3 2025

ClearPoint Neuro reported a solid Q3 with revenue growth of 9% year-over-year, while announcing a strategic merger with IRRAS that is set to expand their market reach and operational scale.

  • Q3 2025 revenue reached $8.9 million, up from $8.1 million in Q3 2024, demonstrating continued growth momentum.
  • The merger with IRRAS is anticipated to create a new $10 billion market opportunity in neuro drug delivery and enhance operational capabilities with an expanded sales team.
  • ClearPoint anticipates significant synergies from the consolidation, including immediate market access to a $0.5 billion segment through the IRRAflow catheter.
  • The company secured an additional $20 million in funding to support merger integration and new growth initiatives following the acquisition.
  • Strategic plans emphasize launching innovative products within existing segments while building a robust ecosystem for drug delivery in partnership with biopharma entities.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 11, 2026
EPS-1.00
Book Value0.63
Price to Book18.54
Debt/Equity337.50
% Insiders8.245%
Growth
Revenue Growth0.43%
Estimates
Forward P/E-12.38
Forward EPS-0.94
Target Mean Price22.00

DCF Valuation

Tweak assumptions to recompute fair value for ClearPoint Neuro, Inc. (CLPT)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

ClearPoint Neuro, Inc. Logo ClearPoint Neuro, Inc. Analysis (CLPT)

United States Health Care Official Website Stock

Is ClearPoint Neuro, Inc. a good investment? ClearPoint Neuro, Inc. (CLPT) is currently trading at 11.64 USD. Market analysts have a consensus price target of 22.00 USD. This suggests a potential upside from current levels.

Earnings Schedule: ClearPoint Neuro, Inc. is expected to release its next earnings report on Aug. 11, 2026. The market consensus estimate for Forward EPS is -0.94.

Investor FAQ

Does ClearPoint Neuro, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is ClearPoint Neuro, Inc.?

ClearPoint Neuro, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Aug. 11, 2026. The company currently has a trailing EPS of -1.00.

Company Profile

ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula. It also provides ClearPoint software, which guides the physician in surgical planning, device alignment, navigation to the target, and procedure monitoring; ClearPoint Prism Neuro laser therapy system to necrotize or coagulate soft tissue; and IRRAflow system, an active fluid exchange platform. In addition, the company offers consulting services to its pharmaceutical and other medical technology partners, such as benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and translation from the preclinical to the clinical setting. It has licenses and collaboration agreements with Koninklijke Philips N.V., UCB Biopharma SRL, Clinical Laserthermia Systems AB, University of California, San Francisco, and NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

Exchange Ticker
NMS (United States) CLPT

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
July 27, 2016 0.030000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion